A rapidly progressive, life-threatening postpartum hemorrhage: successful treatment with anti-CD-20 monoclonal antibody

Obstet Gynecol. 2009 Aug;114(2 Pt 2):417-419. doi: 10.1097/AOG.0b013e3181a602c4.

Abstract

Background: Postpartum hemorrhage may be a life-threatening event and may result from coagulation defects.

Case: We report a case of a multigravida woman who developed rapidly progressive postpartum bleeding as a result of acquired factor VIII inhibitors. Repeated laparotomies and massive transfusions failed to achieve adequate control of bleeding. Laboratory studies revealed a prolonged activated partial thromboplastin time, and the presence of specific inhibitors was soon established. The patient responded only partially to steroids and immunotherapy. Upon administration of rituximab, an anti-CD-20 monoclonal antibody, control of bleeding was achieved.

Conclusion: Early diagnosis of acquired hemophilia as a rare cause of postpartum hemorrhage is crucial, because specific therapy may be life saving.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Female
  • Hemophilia A / diagnosis
  • Hemophilia A / drug therapy*
  • Hemophilia A / etiology
  • Humans
  • Immunologic Factors / therapeutic use*
  • Postpartum Hemorrhage / drug therapy*
  • Postpartum Hemorrhage / etiology*
  • Pregnancy
  • Pregnancy Complications, Hematologic / diagnosis
  • Pregnancy Complications, Hematologic / drug therapy*
  • Pregnancy Complications, Hematologic / etiology
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab